|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||87.73 - 89.02|
|52 Week Range||61.14 - 90.33|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.35%|
Biotech stocks face a challenging 2018. Large companies are feeling pressed to do growth-spurring deals while the rally in smaller firms has pushed up their prices. And then there are the management teams ...
In 3Q17, Bioverativ’s (BIVV) drug Alprolix generated revenue of $88.5 million, which reflected a rise of ~4% on a year-over-year (or YoY) basis. In 3Q17, Alprolix contributed ~32.2% of Bioverativ’s net product sales. Alprolix reported revenue of $264.2 million in the first nine months of 2017 (which ended in September 2017) compared to its revenue of $240.5 million in the first nine months of 2016.
As we discussed earlier, Incyte (INCY) reported a 41.6% rise in its revenue to $381.5 million in 3Q17. Further, Wall Street analysts expect a 26.7% rise in Incyte’s revenue to $413.8 million in 4Q17 and a 35.9% rise in its revenue to $1.5 billion for the entirety of 2017. Incyte’s stock price has fallen nearly 4.3% over the last 12 months and nearly 3.9% year-to-date in 2018.
Delaware-based Ignyta (RXDX) is focused on precision medicine in oncology. It endeavors to eradicate residual disease or the source of a reoccurrence of cancer in targeted patient populations. Ignyta is pursuing an integrated therapeutic and diagnostic strategy to treat cancer patients.
U.S. drug approvals are rolling in at about twice last year’s pace, leaving investors with mixed feelings. In 2018, the approach of midterm elections could keep drug prices in the spotlight. Add another challenge for large U.S. biotechs: Their median CEO tenure has plunged from 11 years in 2007 to just one year in 2017, according to a study by investment bank Leerink.
It's been a tale of two biotechs this year, with large cap stocks largely trailing their smaller peers, and the iShares Nasdaq Biotechnology ETF (IBB) trailing the SPDR S&P Biotech ETF (XBI), which, as an equal-weighted fund, is skewed toward smaller companies. Some analysts see the pain for large cap biotechs continuing, and Jefferies' Michael Yee and his team believe that while biotech in general is a good place to invest next year, the bigger names could have a bit of a tougher go of things--although they could still make headway. In addition, we believe the market will be favorable for biotech and tax repatriation is one tailwind that could stimulate a more positive view as large-caps are likely to react well to M&A and SMID-cap is likely to benefit on a more positive Street view towards M&A (hence win-win for large and small biotech).
Biotech has had an interesting year, write Leerink's Geoffrey Porges and Bradley Canino. The first half of the year saw the market cheering the Food and Drug Administration's faster pace of approvals, successful new products, and the receding threat of price controls. Then in the last third of the year, sales growth slowed, due to reimbursement restrictions and competitive pricing.
Investors have cooled on biotechnology stocks, taking some money off the table after enjoying a greater than 25% gain year-to-date through the end of September. Biotech mutual funds and exchange-traded ...
Don't judge an exchange-traded fund by its cover -- obvious advice, but apparently not obvious enough. The SPDR S&P Biotech ETF (XBI) has returned 42% so far this year, more than double that of the iShares ...
Biotech and pharma stocks dipped after the Senate's GOP tax reform leaves the fate of a key tax credit up in the air.
Biotechnology fund outflows persist. For the week ended Nov. 29, biotechnology mutual funds and exchange-traded funds saw outflows of some $329 million, according to Lipper/AMG Data Services, which tracks ...
It can be tricky putting a price tag on a biotech company, especially one that offers no profits but promises of big success one day in the future. Just because someone wearing a lab coat makes a breakthrough, doesn’t necessarily mean a blockbuster drug is on the horizon. Years can pass before it’s clear whether an experimental treatment will generate returns for a drug maker.
Investors appear to be hitting the snooze button on biotechnology stocks. Net flows are slowing after seeing two consecutive weeks of fresh money. Biotech fund flows, including mutual funds and exchange-traded funds, were essentially flat for the week ended Nov. 15.
Loxo's deal with Bayer had a bigger impact on the biotech sector than you'd expect, an industry observer said.
Fresh money marched into biotechnology stock mutual funds and exchange-traded funds for the week ended Nov. 8, the second consecutive week of net inflows in the past six weeks, according to Lipper/AMG data. About $62 million flowed into 100 funds with some $58.7 billion in assets collectively. Flows are critical to biotech stock strength, according to Raymond James analyst Laura Chico. "In our view, biotech strength will likely be driven in part by specialist funds," she said in note published Thursday.